Developing BLF1 as a novel immunotoxin for cancer treatment
One approach to enhancing the natural properties of antibodies is by conjugating them to toxins, especially where tumours have developed resistance to previous therapeutic regimes. Despite considerable research on immunotoxins, to date only diphtheria toxin has been approved for clinical use. One pr...
| Main Author: | |
|---|---|
| Other Authors: | |
| Published: |
University of Sheffield
2017
|
| Subjects: | |
| Online Access: | https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.729496 |